Molecular Biology Reports

, Volume 39, Issue 5, pp 5387–5391 | Cite as

No evidence for PML-RARa bcr1 fusion gene in colorectal cancer



Colorectal cancer is the third most prevalent cancer and a leading cause of cancer death. Metastatic colorectal cancer patients are treated with anti-EGFR monoclonal antibodies in combination with chemotherapy; however, the efficiency is only 10-20% of such patients. An increasing amount of data has demonstrated that response to anti-EGFR therapies is confined to patients with KRAS and BRAF wild type tumors but still some of these patients are non responders to this treatment. The presence of oncogenic deregulation of different members of EGFR downstream signaling or crosstalk molecules could predict the lack of response in these patients. In this study, 40 wild type KRAS and BRAF colorectal tumors were analyzed to elucidate whether PML-RARa bcr1 fusion gene may play a role in colorectal carcinogenesis. Specifically we want to determine if this fusion could be responsible for the inability to respond to anti-EGFR monoclonal antibodies. Here, for the first time it is reported, that PML-RARa bcr1 fusion is not responsible for colorectal tumor development and also, this translocation is not predicting the lack of efficacy of anti-EGFR therapies in wild type KRAS and BRAF colorectal cancer patients. These results also suggest that PML-RARa is unlikely to be a promising target for adjuvant therapy in colorectal cancer patients.


PML-RARa bcr1 EGFR KRAS BRAF Colorectal cancer 



V-raf murine sarcoma viral oncogene homolog B1


Human homolog of the Kirsten rat sarcoma-2 virus oncogene


Epidermal grown factor


Metastatic colorectal cancer


Promyelocytic leukemia (PML) gene and retinoic acid receptor-alpha (RARa) fusion gene



Thanks to Sabrice Guerrier for his technical help. This work was supported by Junta de Castilla y León.

Conflict of interest

The author declares that she has no competing interests.

Supplementary material

11033_2011_1337_MOESM1_ESM.doc (500 kb)
Supplementary material 1 (DOC 500 kb)


  1. 1.
    Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRefGoogle Scholar
  2. 2.
    Ferlay J, Autier P, Boniol M et al (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581–592PubMedCrossRefGoogle Scholar
  3. 3.
    Poston GJ, Figueras J, Giuliante F et al (2008) Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol 26:4828–4833PubMedCrossRefGoogle Scholar
  4. 4.
    Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634PubMedCrossRefGoogle Scholar
  5. 5.
    Di Nicolantonio F, Martini M, Molinari F et al (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705–5712PubMedCrossRefGoogle Scholar
  6. 6.
    Grignani F, Fagioli M, Alcalay M et al (1994) Acute promyelocytic leukemia: from genetics to treatment. Blood 83:10–25PubMedGoogle Scholar
  7. 7.
    Melnick A, Licht JD (1999) Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93:3167–3215PubMedGoogle Scholar
  8. 8.
    Grimwade D, Biondi A, Mozziconacci MJ et al (2000) Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Francais de Cytogenetique Hematologique, Groupe de Francais d’Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European community-concerted action molecular cytogenetic diagnosis in haematological malignancies. Blood 96:1297–1308PubMedGoogle Scholar
  9. 9.
    Rabbitts TH (1994) Chromosomal translocations in human cancer. Nature 372:143–149PubMedCrossRefGoogle Scholar
  10. 10.
    Weis K, Rambaud S, Lavau C et al (1994) Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell 76:345–356PubMedCrossRefGoogle Scholar
  11. 11.
    Kastner P, Chan S (2001) Function of RARalpha during the maturation of neutrophils. Oncogene 20:7178–7185PubMedCrossRefGoogle Scholar
  12. 12.
    Altucci L, Rossin A, Raffelsberger W et al (2001) Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med 7:680–686PubMedCrossRefGoogle Scholar
  13. 13.
    Wang ZG, Delva L, Gaboli M et al (1998) Role of PML in cell growth and the retinoic acid pathway. Science 279:1547–1551PubMedCrossRefGoogle Scholar
  14. 14.
    Dillard AC, Lane MA (2007) Retinol decreases beta-catenin protein levels in retinoic acid-resistant colon cancer cell lines. Mol Carcinog 46:315–329PubMedCrossRefGoogle Scholar
  15. 15.
    Lee MO, Han SY, Jiang S et al (2000) Differential effects of retinoic acid on growth and apoptosis in human colon cancer cell lines associated with the induction of retinoic acid receptor beta. Biochem Pharmacol 59:485–496PubMedCrossRefGoogle Scholar
  16. 16.
    Callari D, Sinatra F, Paravizzini G et al (2003) All trans retinoic acid sensitizes colon cancer cells to hyperthermia cytotoxic effects. Int J Oncol 23:181–188PubMedGoogle Scholar
  17. 17.
    Cabrera CM, Jimenez P, Concha A et al (2004) Promyelocytic leukemia (PML) nuclear bodies are disorganized in colorectal tumors with total loss of major histocompatibility complex class I expression and LMP7 downregulation. Tissue Antigens 63:446–452PubMedCrossRefGoogle Scholar
  18. 18.
    Plevova P, Bouchal J, Fiuraskova M et al (2007) PML and TRF2 protein expression in hereditary and sporadic colon cancer. Neoplasma 54:269–277PubMedGoogle Scholar
  19. 19.
    Vincenzi B, Santini D, Perrone G, et al (2011) PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients. J Cell Physiol. doi: 10.1002/jcp.22801
  20. 20.
    Vallian S, Gaken JA, Trayner ID et al (1997) Transcriptional repression by the promyelocytic leukemia protein, PML. Exp Cell Res 237:371–382PubMedCrossRefGoogle Scholar
  21. 21.
    Fatrai S, van Gosliga D, Han L et al (2011) KRAS(G12 V) enhances proliferation and initiates myelomonocytic differentiation in human stem/progenitor cells via intrinsic and extrinsic pathways. J Biol Chem 286:6061–6070PubMedCrossRefGoogle Scholar
  22. 22.
    Newton CR, Graham A, Heptinstall LE et al (1989) Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 17:2503–2516PubMedCrossRefGoogle Scholar
  23. 23.
    Thelwell N, Millington S, Solinas A et al (2000) Mode of action and application of Scorpion primers to mutation detection. Nucleic Acids Res 28:3752–3761PubMedCrossRefGoogle Scholar
  24. 24.
    Whitcombe D, Theaker J, Guy SP et al (1999) Detection of PCR products using self-probing amplicons and fluorescence. Nat Biotechnol 17:804–807PubMedCrossRefGoogle Scholar
  25. 25.
    Benlloch S, Paya A, Alenda C et al (2006) Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology. J Mol Diagn 8:540–543PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  1. 1.Unidad de InvestigaciónHospital General YagüeBurgosSpain

Personalised recommendations